Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00282308 · BASELINE

Baseline characteristics

A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate · Source last updated 2017-08-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      68
    2. group Id
      BG001
      value
      32
    3. group Id
      BG002
      value
      100
    units
    Participants
groups
  1. description
    Patients received 2 intravenous infusions of rituximab 1000 mg, 14 days apart + methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.
    id
    BG000
    title
    Rituximab + Methotrexate (Group A)
  2. description
    Patients received methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.
    id
    BG001
    title
    Methotrexate (Group B)
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          9.60
          value
          49.7
        2. group Id
          BG001
          spread
          10.51
          value
          49.7
        3. group Id
          BG002
          spread
          9.85
          value
          49.7
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          51
        2. group Id
          BG001
          value
          25
        3. group Id
          BG002
          value
          76
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          17
        2. group Id
          BG001
          value
          7
        3. group Id
          BG002
          value
          24
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Safety population: All patients who received any amount of rituximab or any vaccine.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      68
    2. group Id
      BG001
      value
      32
    3. group Id
      BG002
      value
      100
    units
    Participants
groups
  1. description
    Patients received 2 intravenous infusions of rituximab 1000 mg, 14 days apart + methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.
    id
    BG000
    title
    Rituximab + Methotrexate (Group A)
  2. description
    Patients received methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.
    id
    BG001
    title
    Methotrexate (Group B)
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          9.60
          value
          49.7
        2. group Id
          BG001
          spread
          10.51
          value
          49.7
        3. group Id
          BG002
          spread
          9.85
          value
          49.7
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          51
        2. group Id
          BG001
          value
          25
        3. group Id
          BG002
          value
          76
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          17
        2. group Id
          BG001
          value
          7
        3. group Id
          BG002
          value
          24
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Safety population: All patients who received any amount of rituximab or any vaccine.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice